Premium
Mass Spectrometry–Based Proteomics: A Useful Tool for Biomarker Discovery?
Author(s) -
Gramolini AO,
Peterman SM,
Kislinger T
Publication year - 2008
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2008.18
Subject(s) - biomarker discovery , false positive paradox , biomarker , proteomics , computational biology , mass spectrometry , false positives and false negatives , drug discovery , computer science , bioinformatics , chemistry , biology , chromatography , artificial intelligence , biochemistry , gene
A biomarker is defined as a biological substance (i.e., protein, metabolite, specific post‐translational modification) that can be used to detect a disease, measure its progression or the effects of a treatment. Importantly, a biomarker should be readily accessible (i.e., present within body fluids); it must also provide sufficient sensitivity and specificity to accurately distinguish between true positives, false positives, and false negatives. Even more importantly, detection of the biomarker should provide clinical benefits to the patient (i.e., improved survival and/or quality of life). Due to recent technical advances in biomolecular mass spectrometry, a great deal of effort has gone into the discovery of biomarkers at an international level. In this commentary we set forth our views on how mass spectrometry (MS) could be applied to the discovery of elusive biomarkers ( Figure 1 ).A proteomics‐based biomarker discovery pipeline. A potential biomarker discovery platform could combine global proteomic profiling in tissue (discovery phase) with sensitive quantitation by target‐driven mass spectrometry (MS) (target‐driven validation) of putative biomarkers directly in plasma. ELISA, enzyme‐linked immunosorbent assay; LC‐MS, liquid chromatography–MS; MRM‐MS, multiple reaction monitoring mass spectrometry; MudPIT, multidimensional protein identification technology.Clinical Pharmacology & Therapeutics (2008); 83 , 5, 758–760. doi: 10.1038/clpt.2008.18